

## **Tanespimycin Hydrochloride**

## Catalog No: tcsc0911

Available Sizes

Size: 10mg

Size: 25mg

Size: 100mg

**Size:** 200mg

**Specifications** 

CAS No:

911710-03-7

Formula:

 $\mathsf{C}_{31}\mathsf{H}_{44}\mathsf{CIN}_3\mathsf{O}_8$ 

Pathway:

Autophagy;Metabolic Enzyme/Protease;Cell Cycle/DNA Damage;Autophagy

**Target:** 

Autophagy;HSP;HSP;Mitophagy

### Purity / Grade:

>98%

#### Solubility:

DMSO : ≥ 50 mg/mL (80.37 mM); H2O :

#### **Alternative Names:**

17-AAG (Hydrochloride);NSC 330507 Hydrochloride;CP 127374 Hydrochloride

# **Observed Molecular Weight:** 622.15

Copyright 2021 Taiclone Biotech Corp.




### **Product Description**

17-AAG Hydrochloride is a potent **HSP90** inhibitor with **IC**<sub>50</sub> of 5 nM, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells.

IC50 & Target: IC50: 5 nM (HSP90)<sup>[5]</sup>

*In Vitro:* 17-AAG causes the degradation of HER2, Akt, and both mutant and wild-type AR and the retinoblastoma-dependent G1 growth arrest of prostate cancer cells. 17-AAG inhibits prostate cancer cell lines with  $IC_{50}$ s ranged from 25-45 nM (LNCaP, 25 nM; LAPC-4, 40 nM; DU-145, 45 nM; and PC-3, 25 nM)<sup>[1]</sup>. Combination of 17-AAG (10 nM) and Trastuzumab induces more effective ErbB2-degradation. 17-AAG (0.1-1  $\mu$ M) induces a nearly complete loss of ErbB2 on ErbB2-overexpressing breast cancer cells<sup>[2]</sup>. 17-AAG inhibits cell growth and induces G2/M cell cycle arrest and apoptosis in CCA cells together with the down-regulation of Bcl-2, Survivin and Cyclin B1, and the up-regulation of cleaved PARP<sup>[3]</sup>.

*In Vivo:* 17-AAG (25-200 mg/kg, i.p.) causes a dose-dependent decline in AR, HER2, and Akt expression in prostate cancer xenografts. 17-AAG treatment at doses sufficient to induce AR, HER2, and Akt degradation results in the dose-dependent inhibition of androgen-dependent and -independent prostate cancer xenograft growth without toxicity<sup>[1]</sup>. 17-AAG (60 mg/kg) with paclitaxel (60 mg/kg) and rapamycin (30 mg/kg) inhibits A549 and MDA-MB-231 tumor growth far more potently than paclitaxel-containing micelles and effected tumor cures in MDA-MB-231 tumor-bearing animals by tail vein injection<sup>[4]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.